{
    "id": 1190,
    "fullName": "KIT mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KIT mutant indicates an unspecified mutation in the KIT gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "mutant",
    "createDate": "07/29/2014",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3968,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4316,
                    "pubMedId": 25729899,
                    "title": "Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25729899"
                },
                {
                    "id": 5211,
                    "pubMedId": 25193432,
                    "title": "GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193432"
                },
                {
                    "id": 5212,
                    "pubMedId": 26276366,
                    "title": "The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26276366"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9777,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 4316,
                "therapyName": "Ripretinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7598,
                    "pubMedId": null,
                    "title": "DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study",
                    "url": "http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3305,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11853,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9871,
                    "pubMedId": 28843487,
                    "title": "STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28843487"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15301,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I (NAVIGATOR) trial, Ayvakit (avapritinib) treatment resulted in an objective response rate of 13% (7/52, 7 partial responses) and a disease control rate of 63% (33/52) in patients with KIT-mutant gastrointestinal stromal tumor (The CTOS 2018 Annual Meeting, Nov 14-17, Rome Italy, Paper 012 3027631; NCT02508532).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13026,
                    "pubMedId": null,
                    "title": "AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA",
                    "url": "https://www.ctos.org/Portals/0/PDF/2018%20CTOS%20Final%20Program.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7788,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 2284,
                "therapyName": "BGJ398 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6494,
                    "pubMedId": 25673643,
                    "title": "FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6080,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",
            "molecularProfile": {
                "id": 22438,
                "profileName": "RUNX1 - RUNX1T1 KIT mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1127,
                    "pubMedId": 18648004,
                    "title": "Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18648004"
                },
                {
                    "id": 5289,
                    "pubMedId": 25111512,
                    "title": "Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25111512"
                },
                {
                    "id": 5290,
                    "pubMedId": 16384925,
                    "title": "Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16384925"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1214,
            "profileName": "KIT mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22438,
            "profileName": "RUNX1 - RUNX1T1 KIT mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}